Moreover, the 36-month beta value for ASBP is 0.90.
The public float for ASBP is 39.39M and currently, short sellers hold a 6.35% of that float. On June 12, 2025, ASBP’s average trading volume was 12.35M shares.
ASBP) stock’s latest price update
The stock of Aspire Biopharma Holdings Inc (NASDAQ: ASBP) has increased by 5.81 when compared to last closing price of 0.38. Despite this, the company has experienced a 2.23% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-06-10 that Michael Howe – who currently serves as an Independent Board Member – to assume CEO role on June 10, 2025 Michael’s career spans nationally recognized brands such as MinuteClinic, Procter & Gamble, PepsiCo, CEO of Arby’s, and as an early-stage investor/board member in healthcare and software businesses HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, today announced that its Board of Directors has elected Michael C. Howe, as the Company’s new chief executive officer.
ASBP’s Market Performance
Aspire Biopharma Holdings Inc (ASBP) has experienced a 2.23% rise in stock performance for the past week, with a 20.82% rise in the past month, and a -46.12% drop in the past quarter. The volatility ratio for the week is 6.62%, and the volatility levels for the past 30 days are at 27.99% for ASBP. The simple moving average for the last 20 days is 15.42% for ASBP stock, with a simple moving average of -94.51% for the last 200 days.
ASBP Trading at -4.34% from the 50-Day Moving Average
After a stumble in the market that brought ASBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.48% of loss for the given period.
#####
#####
Stock Fundamentals for ASBP
The total capital return value is set at 0.33. Equity return is now at value -490.07, with -234.69 for asset returns.
Based on Aspire Biopharma Holdings Inc (ASBP), the company’s capital structure generated -4.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.21. The debt to equity ratio resting at -0.82. The interest coverage ratio of the stock is -0.56.
Currently, EBITDA for the company is -11.65 million with net debt to EBITDA at -0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.22.
Conclusion
To wrap up, the performance of Aspire Biopharma Holdings Inc (ASBP) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
